Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics, Inc. - Common Stock (NQ:VTGN)

0.2259 -0.0102 (-4.32%)
Delayed Quote Updated: 12:51 PM EDT, Oct 12, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces FDA Fast Track Designation for Development of Proprietary MDD Treatment
Via Investor Brand Network
News headline image
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder
From Vistagen
Via Business Wire
News headline image
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder
From Vistagen
Via Business Wire
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Publishes Positive Preclinical Findings Related to AV-101
Via Investor Brand Network
News headline image
Vistagen Announces Publication in Cells Demonstrating AV-101’s Potential for Treating Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease
From Vistagen
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q2 2023 Financial Report, Corporate Update
Via Investor Brand Network
News headline image
Vistagen Reports Second Quarter Financial Results and Provides Corporate Update
From Vistagen
Via Business Wire
News headline image
Earnings Scheduled For November 10, 2022 ↗
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report earnings for its third quarter. 
Via Benzinga
News headline image
Earnings Outlook For VistaGen Therapeutics ↗
VistaGen Therapeutics (NASDAQ:VTGN) is set to give its latest quarterly earnings report on Thursday, 2022-11-10. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q2 2023 Financial Results Call, Webcast
Via Investor Brand Network
News headline image
Vistagen to Report Fiscal Year 2023 Second Quarter Financial Results on November 10, 2022
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Stifel 2022 Healthcare Conference
Via Investor Brand Network
News headline image
Vistagen to Present at Stifel 2022 Healthcare Conference
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Virtual Roundtable on Innovative Approaches to Mental Health Treatment
Via Investor Brand Network
News headline image
Vistagen to Host Concordia Live Webinar on Mental Health with Leaders from McKinsey Health Institute, WEVO, and In KidZ
From Vistagen
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Report on 2022 Annual Meeting of Stockholders Voting, Partial Adjournment
Via Investor Brand Network
News headline image
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
From Vistagen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Shares Shareholder Voting Recommendations from Leading Proxy Advisory Firms
Via Investor Brand Network
News headline image
Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
From Vistagen Therapeutics, Inc.
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) CEO to Participate at Cantor Neurology & Psychiatry Conference
Via Investor Brand Network
News headline image
Vistagen to Participate at Cantor Neurology & Psychiatry Conference
From Vistagen
Via Business Wire
News headline image
Why ECMOHO Is Trading Lower By 29%; Here Are 28 Stocks Moving Premarket ↗
Gainers Ampio Pharmaceuticals, Inc. (NYSE: AMPE) rose 17.8% to $0.0942 in pre-market trading after declining around 5% on Tuesday. 
Via Benzinga
News headline image
Vistagen CEO Shawn Singh to Join Executive Roundtable Discussing Mental Health at Concordia Annual Summit
From Vistagen
Via Business Wire
News headline image
Vistagen Presents Poster at Psych Congress 2022 Highlighting Effect of PH94B on Nasal Electrogram Responses and Biomarkers of Autonomic Nervous System Activity in Healthy Human Subjects
From Vistagen
Via Business Wire
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Why SciSparc Is Trading Higher By 68%, Here Are 48 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Akerna Corp. (NASDAQ: KERN) shares rose 81.2% to $0.2355 after gaining 8% on Tuesday. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news moving them. 
Via InvestorPlace
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation Schedule for Upcoming Conferences
Via Investor Brand Network
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.